本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 证券代码：920275 证券简称：驱动力 公告编号：2026-005 广东驱动力生物科技集团股份有限公司 投资者关系活动记录表 □媒体采访 √现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2026 年 3 月 26 日 活动地点：公司会议室 回答：公司主营业务是研发、生产、销售具有提升动物造血能力的添加剂、 添加剂预混料等，市场空间巨大，但目前公司的市场占有率还比较小，整体市场 也是在不断的培育发展中，在生猪行业还有很多的市场机会待开发、待突破。实 际上，公司的产品可以帮助养猪户降本增效，在生猪价格下行的情况下，能够帮 助客户降低成本减少损失，目前很多下游企业尚未认识到造血营养的必要性、还 不了解公司产品，没有进行试验，这种情况下公司需要在宣传方面投入更多的精 力。另外，公司产品是多元化的，即使生猪行情不好，公司也可以在其他领域加 强产品研发和市场拓展， ...

Core Insights - The company reported a revenue of 76.81 million yuan for 2025, representing a year-on-year increase of 7.07%, while net profit decreased by 67.42% to 4.55 million yuan [1] - The decline in net profit is attributed to a shift in sales mix, with higher-margin products' sales decreasing by approximately 18.45% and lower-margin products increasing by about 17.09%, leading to a comprehensive gross margin decline of around 9.87% [1] - The company experienced a significant increase in management expenses and a decrease in investment income from joint ventures, contributing to the overall decline in profitability [1] Financial Performance - In 2022 and 2023, the company's net profit halved, with declines of 56.52% and 66.01% respectively [2] - A projected net profit increase of 136.31% for 2024 is expected due to a higher sales proportion of high-margin products and a positive change in credit impairment losses [2] - As of the end of the reporting period, total assets are estimated at 242 million yuan, a decrease of 1.87% year-on-year, and equity attributable to shareholders is projected at 233 million yuan, down 2.10% [1] Strategic Developments - On October 10, 2025, the company established Guangzhou Pet Xiaoxing Pet Products Co., Ltd., holding a 51% stake, marking its entry into the pet industry [2] - The company aims to explore new application scenarios for its blood products in pet food, although it emphasizes that the pet business is not yet a primary focus [4] - Previous involvement in the pet food sector was limited, but the new venture indicates a strategic shift in response to pressures on core business [2][4] Market Performance - As of February 26, the company's stock price decreased by 1.53%, closing at 8.99 yuan per share, with a total market capitalization of 1.433 billion yuan [5]

Financial Performance - The company's operating revenue for the reporting period is expected to be CNY 76.81 million, a year-on-year increase of 7.07%[4] - The total profit is projected to be CNY 4.65 million, representing a significant decline of 69.32% compared to the previous year[4] - The net profit attributable to shareholders is expected to be CNY 4.55 million, down 67.42% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be CNY 4.43 million, a decrease of 64.00%[4] - The basic earnings per share are projected to be CNY 0.03, a decline of 67.42% compared to the previous year[4] Assets and Equity - The total assets at the end of the reporting period are estimated to be CNY 241.78 million, a decrease of 1.87% compared to the beginning of the period[4] - The equity attributable to shareholders is expected to be CNY 233.47 million, down 2.10% year-on-year[4] Operational Challenges - The decrease in net profit is primarily due to a shift in product sales, with higher-margin products' sales proportion dropping by approximately 18.45%[6] - The company experienced a significant increase in management expenses, approximately CNY 1.31 million, impacting overall profitability[7] Cautionary Note - The report emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[10]

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Financial Forecast - The company forecasts a net profit of approximately CNY 35 million to CNY 55 million for the year 2025, representing a decline of 60.65% to 74.96% compared to the previous year's net profit of CNY 139.768 million[5]. - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm, emphasizing the need for investors to be cautious and aware of investment risks[8]. Profit Decline Factors - The decrease in net profit is attributed to a lower sales proportion of high-margin hematopoietic series products 1 and 2, while the sales proportion of lower-margin hematopoietic series product 3 increased, leading to a reduction in overall gross profit margin[6]. - The company experienced an increase in management expenses due to higher intermediary service fees and personnel compensation, contributing to the decline in net profit[7]. - The investment income from joint ventures decreased during the reporting period, further impacting the net profit negatively[7].

证券代码：920275 证券简称：驱动力 公告编号：2026-001 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易内容 | 预计 2026 | 年 | 2025 | 年与关联方 | 预计金额与上年实际发生金 | | --- | --- | --- | --- | --- | --- | --- | | | | 发生金额 | | | 实际发生金额 | 额差异较大的原因 | | 购买原材料、 | | | | | | 2025年预计关联方交易额200 万元，下半年因关联方供应商 | | 燃料和动力、 | 原材料采购 | 1,500,000 | | | 989,350 | 供应量不足，本公司从其他供 | | 接受劳务 | | | | | | 应商补货，导致关联交易实际 | | | | | | | | 发生额低于预期。 | | 销售产品、商 | | | | | | | | 品、提供劳务 | | | | | | | | 委托关 ...

已披露的公开承诺事项均正常履行，不存在超期未履行完毕及违反承诺的情形，离 任后将继续履行相关承诺。承诺内容详见 2021 年公司向不特定合格投资者公开发行股 票并在北京证券交易所上市的《公开发行股票说明书》之"第四节发行人基本情况"之 "九、重要承诺"。 二、合规性说明及影响 （一）人员变动的合规性说明 陆应诚先生离任符合相关法律法规、部门规章、业务规则和公司章程等规定，未导 致公司董事会成员人数低于法定最低人数，未导致董事会中兼任高级管理人员的董事和 由职工代表担任的董事人数超过公司董事总数的二分之一，未导致董事会或者其专门委 员会中独立董事所占的比例不符合相关规则或者公司章程的规定，未导致独立董事中欠 缺会计专业人士。 （二）人员变动对公司的影响 证券代码：920275 证券简称：驱动力 公告编号：2026-002 广东驱动力生物科技集团股份有限公司 高级管理人员离任公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、高级管理人员离任的基本情况 本公司陆应诚先生，因到龄退休，自 2026 年 1 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]